HHS proposed changes that would roll back many Biden-era policies, eliminate most health tech certification criteria,and ...

PCR is a mainstay in diagnostics, but whether a sample is collected at a clinic or at home, such tests require sending a sample to a lab and then waiting for results. A new FDA authorized ...

Like most industries, healthcare is experiencing financial pressure and unprecedented AI advancements. Organizations are also grappling with a political and economic environment that is more dynamic ...

Across the healthcare industry, patients are demanding more transparency. They want control over their health and access to their healthcare data. And they’re right – patients should be at the center ...

Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized products each offer ...

The FDA has approved a pill version of Novo Nordisk’s blockbuster drug Wegovy, giving the company the lead in the pharmaceutical industry pursuit of oral weight loss drugs while also providing ...

New research suggests that health systems are struggling to effectively use AI to improve patient engagement. The study, released earlier this month, found that while investments in tools like ambient ...

As a geriatrician, I see the significant gap between what policies intend and the reality in practice, and it’s not always what you expect. We measure blood pressure, weight, and cholesterol without ...

CMS has been trying to scale value-based care for decades with mixed results — but the agency’s newly announced ACCESS model could represent a more meaningful step toward aligning payment with ...

Deloitte’s 2026 Healthcare Outlook shows that while more than two-thirds of U.S. healthcare leaders expect to outperform competitors, rising policy uncertainty is pushing greater focus on digital care ...

More than 50 major insurers have pledged to streamline prior authorization starting in 2026, but providers remain cautiously optimistic and skeptical that the changes will truly reduce burden or ...

Comeback stories are often the stuff of movies, but GSK is showing they can also happen in pharmaceuticals. The multiple myeloma medicine Blenrep has returned to the market three years after GSK ...